

Faculty disclosures

Prof. Dr. Meinrad Beer has declared no conflict of interest.

Prof. Dr. Walter De Wever has declared no conflict of interest.

Prof. Dr. Ernst Eber has declared no conflict of interest.

Prof. Monika Gappa has declared no conflict of interest.

Prof. John Gibson has declared no conflict of interest.

Dr. Hadchouel-Duvergé has declared no conflict of interest.

Prof. Dr. Hamutcu Ersu has declared no conflict of interest.

Dr. Gabor Kovacs has declared to receive a grant from Actelion, as well as honoraria or consultation fees from Actelion, Bayer, MSD, Ferrer, GSK, Boehringer-Ingelheim, Novartis and Chiesi.

Prof. Stylianos Loukides has declared no conflict of interest.

Dr. Florian Maurer has declared no conflict of interest.

Prof. Fabio Midulla has declared no conflict of interest.

Dr. Daniel Misch has declared no conflict of interest.

Prof. Paolo Navalesi has declared the following: royalties by Intersurgical SPA for Helmet Next invention Research grant by Draeger, speaker fees by MSD, Novartis, Guidotti, Orion, Philips, Resmed, and Getinge.

Dr. Marielle W. H. Pijnenburg has declared no conflict of interest.

Dr. Najib M. Rahman has declared to provide consultancy for Rocket Medical UK and BD.

Prof. Dr. Nicolas Regamey has declared no conflict of interest.

Prof. Sophia E. Schiza has declared no conflict of interest.

Prof. Dr. Tobias Welte has declared to have received grants from the German Ministry of Research and Education, the German Research Organization (DFG), the EU, Grifols, Insmmed and Vertex, as well as fees for lectures/advisory board from AstraZeneca, Basilea, Bayer, Chiesi, Grifols, GSK, Infectopharm, Insmmed, Janssen, MSD, Novartis, Pfizer, Roche, Shionogi, and Zambon.

Dr. Marlies S. Wijzenbeek has declared to have received speaker and consultancy fees and grants from Boehringer Ingelheim and Hoffmna La Roche, as well as provided consultancy for Galapagos, Respivant and Galecto.